Chemotherapy in the structure of complex treatment of patients with recurrent intracranial meningiomas
K. K. Kukanov,
S. S. Sklyar,
D A. Sitovskaya,
K. A. Samochernykh,
K. I. Sebelev,
M. V. Dikonenko,
V. E. Olyushin https://doi.org/10.56618/2071-2693_2024_16_2_57
EDN: LVWGYB
Abstract
INTRODUCTION. High level expression in tumor cells of various cellular growth factors, their receptors and activation of intracellular signaling pathways take an important part in recurrence of intracranial meningiomas (Grade III). There is a group of patients with aggressive meningiomas characterized by frequent recurrences and low survival rate. The following surgery is associated with high risk of appearance or worsening of neurological deficit, radical tumor removal is not always possible. Radiotherapy is also limited in some cases or not effective enough.
AIM. To evaluate the degree of development of the theme of chemotherapy use in patients with meningiomas of different anaplasia degree according to the world literature data; to present our own data on chemotherapeutic treatment of a patient with recurrent meningioma.
MATERIALS AND METHODS. The search of printed works in Pubmed, EMBASE, Cohrane Library and eLibrary databases was carried out on the issue of chemotherapeutic treatment use in patients with intracranial meningiomas. There is a description of a clinical case of chemotherapy use in complex treatment of a patient with recurrent intracranial anaplastic meningioma in Polenov Neurosurgical Institute — the branch of Almazov National Medical Research Centre.
RESULTS. The results of some experimental studies and clinical use of chemotherapeutic drugs of different groups in patients with intracranial meningiomas are presented. Our own data on chemotherapy use in a patient with recurrent meningioma are given.
CONCLUSION. Specific antitumor treatment is a part of complex treatment for patients with recurrent meningiomas Grade II–III. The efficiency and safety of this therapy have been proved in some studies and also shown in our clinical example.
Keywords
meningioma,
recurrence,
progression,
chemotherapeutic treatment,
target therapy,
Bevacizumab,
disease-free period
Supporting agencies: The work was carried out as part of the state assignment No. 123021000128-4 “Development of a new technology for treating patients with secondary brain tumors and recurrent meningiomas”.
About the Authors
K. K. Kukanov
Polenov Neurosurgery Institute – the branch of Almazov National Medical Research Centre
Russian Federation
Russian Federation
Konstantin K. Kukanov – Cand. of Sci. (Med.), Neurosurgeon
of the Highest Qualification Category of the Neurosurgical
Department No. 4, Senior Researcher at the Institute of
Neuro-Oncology
12 Mayakovskogo street, St. Petersburg,191025
S. S. Sklyar
Polenov Neurosurgery Institute – the branch of Almazov National Medical Research Centre
Russian Federation
Russian Federation
Sofia S. Sklyar – Cand. of Sci. (Med.), Neurosurgeon, Оncologist, Senior Researcher at the Research Laboratory of
Neurooncology
12 Mayakovskogo street, St. Petersburg,191025
D A. Sitovskaya
Polenov Neurosurgery Institute – the branch of Almazov National Medical Research Centre
Russian Federation
Russian Federation
Daria A. Sitovskaya – Pathologist, Research Fellow at the Research Institute of Pathomorphology of the Nervous System
12 Mayakovskogo street, St. Petersburg,191025
K. A. Samochernykh
Polenov Neurosurgery Institute – the branch of Almazov National Medical Research Centre
Russian Federation
Russian Federation
Konstantin A. Samochernykh – Dr. of Sci. (Med.), Professor of the Russian Academy of Sciences, Neurosurgeon of the Highest Category at the Department of Neurosurgery for Children No. 7, Director
12 Mayakovskogo street, St. Petersburg,191025
K. I. Sebelev
Polenov Neurosurgery Institute – the branch of Almazov National Medical Research Centre
Russian Federation
Russian Federation
Konstantin I. Sebelev – Dr. of Sci. (Med.), Full Professor, Head at the Department of Radiation Diagnostics No. 4, Leading Researcher at the Institute of Pathomorphology of the Nervous System
12 Mayakovskogo street, St. Petersburg,191025
M. V. Dikonenko
Polenov Neurosurgery Institute – the branch of Almazov National Medical Research Centre
Russian Federation
Russian Federation
Miсhail V. Dikonenko – Neurosurgeon, Junior Research Fellow of the Stereotactic and Functional Neurosurgery Group at the Research Institute of Neuro-Oncology
12 Mayakovskogo street, St. Petersburg,191025
V. E. Olyushin
Polenov Neurosurgery Institute – the branch of Almazov National Medical Research Centre
Russian Federation
Russian Federation
Victor E. Olyushin – Dr. of Sci. (Med.), Full Professor, Honored Doctor of Russia, Neurosurgeon of the Highest Qualification Category, Chief Researcher at the Institute of Neuro-Oncology
12 Mayakovskogo street, St. Petersburg,191025
References
1. Roland G., Pantelis S., Michael D. et al. EANO guideline on the diagnosis and management of meningiomas. Neurooncol. 2021;23(11):1821–1834. Doi: https://doi.org/10.1093/neuonc/noab150.
2. Priya K., Sean A., Roxanne T. et al. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv. 2022;4(1):1–10. Doi: https://doi.org/10.1093/noajnl/vdac123.
3. Maximilian J., Anna S., Priscilla K., Matthias P. Emerging systemic treatment options in meningioma. J Neurooncolog. 2023; 161(2):245–258. Doi: http://doi.org/10.1007/s11060-022-04148-8.
4. Ostrom Q. T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J. S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology. 2020;22(1):1–96. Doi: https://doi.org/10.1093/neuonc/noaa200.
5. Kukanov K. K., Vorobyova O. M., Zabrodskaya Yu. M., Potemkina E. G., Ushanov V. V., Tastanbekov M. M., Ivanova N. E. Intracranial meningiomas: clinical, intrascopic and pathomorphological causes of recurrence (literature review). Siberian journal of oncology. 2022;21(4):110–123. (In Russ.)]. Doi: https://doi.org/10.21294/1814-4861-2022-21-4-110-123.
6. Kukanov K. K., Ushanov V. V., Zabrodskaya Yu. M., Tastanbekov M. M., Vorobyova O. M., Sitovskaya D. A., Dikonenko M. V. Ways to personalize the treatment of patients with relapse and continued growth of intracranial meningiomas. Russian Journal for Personalized Medicine. 2023;3(3):48–63. (In Russ.)]. Doi: https://doi.org/10.18705/2782-38062023-3-3-48-63.
7. Certificate of state registration of the database No. RU 2023621571. Register of patients with recurrence and continued growth of intracranial meningiomas; Kukanov K. K., Ushanov V. V., Voinov N. E. 02.05.2023. (In Russ.)]. EDN: https://elibrary.ru/vbrsbm.
8. Violaris K., Katsarides V., Sakellariou P. The Recurrence Rate in Meningiomas: Analysis of Tumor Location, Histological Grading, and Extent of Resection. Open J Modern Neurosurg. 2012;(2):6–10. Doi: https://doi.org/10.4236/ojmn.2012.21002.
9. Kotecha R. S., Pascoe E. M., Rushing E. J., RorkeAdams L. B., Zwerdling T., Gao X., Li X., Greene S., Amirjamshidi A., Kim S. K., Lima M. A., Hung P. C., Lakhdar F., Mehta N., Liu Y., Devi B. I., Sudhir B. J., Lund-Johansen M., Gjerris F., Cole C. H., Gottardo N. G. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011;12(13):1229–1239. Doi: https://doi.org/10.1016/S1470-2045(11)70275-3.
10. Huntoon K., Toland A. M. S., Dahiya S. Meningioma: a review of clinicopathological and molecular aspects. Front Oncol. 2020;10(10):1–14. Doi: https://doi.org/10.3389/fonc.2020.579599.
11. Commins D., Atkinson R., Burnett M. Review of meningioma histopathology. Neurosurg Focus. 2007;23(4):1–9. Doi: https://doi.org/10.3171/FOC-07/10/E3.
12. Brastianos P., Galanis E., Butowski N. et al. Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019;21(1):118–131. Doi: http://doi.org/10.1093/neuonc/noy136.
13. Chen R., Aghi M. K. Atypical meningiomas. Handb Clin Neurol. 2020;(170):233–244. Doi: https://doi.org/10.1016/B978-0-12-822198-3.00043-4.
14. Debus J., Wuendrich M., Pirzkall A. et al. High efficacy of fractionated stereotactic radiotherapy of large baseof-skull meningiomas: long-term results. J Clin Oncol. 2001;19(15):3547–3553. Doi: https://doi.org/10.1200/JCO.2001.19.15.3547.
15. Cao X., Hao S., Wu Z. et al. Treatment Response and Prognosis After Recurrence of Atypical Meningiomas. World Neurosurg. 2015;84(4):1014–1019. Doi: https://doi.org/10.1016/j.wneu.2015.05.032.
16. Al-Rashed M., Foshay K., Abedalthagafi M. Recent Advances in Meningioma Immunogenetics. Front Oncol. 2020;(9):1472. Doi: https://doi.org/10.3389/fonc.2019.01472.
17. Chamberlain M. C., Tsao-Wei D. D., Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;62(7):1210–1212. Doi: https://doi.org/10.1212/01.wnl.0000118300.82017.f4.
18. Chamberlain M. C., Tsao-Wei D. D., Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3):271–276. Doi: https://doi.org/10.1007/s11060-005-9093-x.
19. Chamberlain M. C. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996;84(5):733–736. Doi: https://doi.org/10.3171/jns.1996.84.5.0733.
20. Raizer J., Grimm S., Rademaker A. et al. A phase II trial of PTK787/ ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014;117(1):93–101. Doi: https://doi.org/10.1007/s11060-014-1358-9.
21. Kaley T., Wen P., Schiff D. et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116–121. Doi: https://doi.org/10.1093/neuonc/nou148.
22. André F., Ciruelos E., Juric D. et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptorpositive, human epidermal growth factor receptor-2– negative advanced breast cancer: fnal overall survival results from SOLAR-1. Ann Oncol. 2020;32(2):208–217. Doi: https://doi.org/10.1016/j.annonc.2020.11.011.
23. Findakly S., Choudhury A., Daggubati V. et al. Meningioma cells express primary cilia but do not transduce ciliary hedgehog signals. Acta Neuropathol. 2020;8(1):114. Doi: https://doi.org/10.1186/s40478-020-00994-7.
24. Nassiri F., Liu J., Patil V. et al. A clinically applicable integrative molecular classifcation of meningiomas. Nature. 2021;597(7874):119–125. Doi: https://doi.org/10.1038/s41586-021-03850-3.
25. NCCN Clinical Practice Guidelines in Oncology (NCCN Gudelines®). Central Nervous System Cancer. 2023; Ver. 1.URL: https://www.nccn.org/ [Accessed 03 March 2024].
26. Li Y., Veliceasa D., Lamano J. et al. Systemic and local immunosuppression in patients with highgrade meningiomas. Cancer Immunol Immunother. 2019;68(6):999–1009. Doi: https://doi.org/10.1007/s00262-019-02342-8.
27. Barani I., Parsa A. Adaptive hybrid surgery: feasibility of planned subtotal resection of benign skull base tumors followed by radiosurgery to minimize morbidity without compromising tumor control. Int J Radiat Oncol Biol Phys. 2012;84(3):278–279. Doi: https://doi.org/10.1016/j.ijrobp.2012.07.726.
28. Olar A., Wani K., Wilson C. et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol. 2017;133(3):431–444. Doi: https://doi.org/10.1007/s00401-017-1678-x.
29. Shah N., Tancioni I., Ward K. et al. Analyses of merlin/ NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 2014;134(1):104–111. Doi: https://doi.org/10.1016/j.ygyno.2014.04.044.
30. Goodwin J., Crowley J., Eyre H., Stafford B., Jaeckle K., Townsend J. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15(1):75–77. Doi: http://doi.org/10.1007/BF01050266.
31. Grigoryan M. V., Olyushin V. E., Ulitin A. Yu., Matsko M. V. Chemotherapy in the complex treatment of intracranial anaplastic meningiomas. Russian neurosurgical journal named after professor A. L. Polenov. 2011: 3(4):6–11. (In Russ.)]. EDN: https://elibrary.ru/rcqbmv.
32. Lou E., SumrallA.L., Turner S. et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;(109):63–70. Doi: https://doi.org/10.1007/s11060-012-0861-0.
33. Reardon D., Norden A., Desjardins A. et al. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012;(106):409–415. Doi: https://doi.org/10.1007/s11060-011-0687-1.
34. Shih K., Chowdhary S., Rosenblatt P. et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol. 2016;(129):281–288. Doi: https://doi.org/10.1007/s11060-016-2172-3.
35. Mazza E., Brandes A., Zanon S. et al. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2016;(77):115–120. Doi: https://doi.org/10.1007/s00280-015-2927-0.
36. Preusser M., Silvani A., Le Rhun E. et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol. 2022. Doi: https://doi.org/10.1093/neuonc/noab243.
37. Belanger K., Ung T. H., Damek D. et al. Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. BMC Cancer. 2022;(22):367. Doi: https://doi.org/10.1186/s12885-022-09340-7.
Review
For citations:
Kukanov K.K., Sklyar S.S., Sitovskaya D.A., Samochernykh K.A., Sebelev K.I., Dikonenko M.V., Olyushin V.E. Chemotherapy in the structure of complex treatment of patients with recurrent intracranial meningiomas. Russian Neurosurgical Journal named after Professor A. L. Polenov. 2024;16(2):57–68. (In Russ.) https://doi.org/10.56618/2071-2693_2024_16_2_57. EDN: LVWGYB
Views:
94
Email this article 